215 related articles for article (PubMed ID: 27989550)
21. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome).
Ranade R; Kand P; Basu S
Nucl Med Commun; 2015 Oct; 36(10):1014-20. PubMed ID: 26049373
[TBL] [Abstract][Full Text] [Related]
22. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid.
Caobelli F; Chiaravalloti A; Evangelista L; Saladini G; Schillaci O; Vadrucci M; Scalorbi F; Donner D; Alongi P;
Ann Nucl Med; 2018 Jan; 32(1):7-15. PubMed ID: 28986764
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic Accuracy of 18F-FDG PET/CT in Patients With Biochemical Evidence of Recurrent, Residual, or Metastatic Medullary Thyroid Carcinoma.
Rodríguez-Bel L; Sabaté-Llobera A; Rossi-Seoane S; Reynés-Llompart G; Vercher Conejero JL; Cos-Domingo M; Moreno-Llorente P; Pérez-Maraver M; Cortés-Romera M; Gámez Cenzano C
Clin Nucl Med; 2019 Mar; 44(3):194-200. PubMed ID: 30562193
[TBL] [Abstract][Full Text] [Related]
24. PET and PET/CT in the management of thyroid cancer.
Basu S; Urhan M; Rosenbaum J; Alavi A
Methods Mol Biol; 2011; 727():205-24. PubMed ID: 21331936
[TBL] [Abstract][Full Text] [Related]
25. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
26. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.
Rubello D; Rampin L; Nanni C; Banti E; Ferdeghini M; Fanti S; Al-Nahhas A; Gross MD
Eur J Surg Oncol; 2008 May; 34(5):581-6. PubMed ID: 17892923
[TBL] [Abstract][Full Text] [Related]
27. PET/CT imaging of thyroid cancer.
Mosci C; Iagaru A
Clin Nucl Med; 2011 Dec; 36(12):e180-5. PubMed ID: 22064103
[TBL] [Abstract][Full Text] [Related]
28. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
[TBL] [Abstract][Full Text] [Related]
29. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
[TBL] [Abstract][Full Text] [Related]
30. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.
Archier A; Heimburger C; Guerin C; Morange I; Palazzo FF; Henry JF; Schneegans O; Mundler O; Abdullah AE; Sebag F; Imperiale A; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1027-33. PubMed ID: 26497699
[TBL] [Abstract][Full Text] [Related]
31. Positron Emission Tomography/Computed Tomography in Thyroid Cancer: An Updated Review.
Chandekar KR; Satapathy S; Bal C
PET Clin; 2024 Apr; 19(2):131-145. PubMed ID: 38212213
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
[TBL] [Abstract][Full Text] [Related]
33. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
[TBL] [Abstract][Full Text] [Related]
34. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
[TBL] [Abstract][Full Text] [Related]
35. Prospective study on the clinical relevance of
Califano I; Pitoia F; Chirico R; De Salazar A; Bastianello MJ
Endocrine; 2022 Jun; 77(1):143-150. PubMed ID: 35489000
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
[TBL] [Abstract][Full Text] [Related]
37. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
38. Predictive Value of
Werner RA; Schmid JS; Higuchi T; Javadi MS; Rowe SP; Märkl B; Aulmann C; Fassnacht M; Kroiss M; Reiners C; Buck AK; Kreissl MC; Lapa C
J Nucl Med; 2018 May; 59(5):756-761. PubMed ID: 29025983
[TBL] [Abstract][Full Text] [Related]
39. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
40. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.
Nanni C; Rubello D; Fanti S; Farsad M; Ambrosini V; Rampin L; Banti E; Carpi A; Muzzio P; Franchi R
Biomed Pharmacother; 2006 Sep; 60(8):409-13. PubMed ID: 16891093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]